NCIC CTG BR.19: Gefitinib Therapy for Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC)

CME test	Downloadable PDF	PowerPoint slides	CME Information and Faculty Disclosures
Read Dr Love's original email (from July 29, 2010)			Subscribe to Dr Love's email alerts

Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Roy S Herbst, MD, PhD (6/23/10) and Lecia V Sequist, MD, MPH (6/18/10)

 

Goss GD et al. A Phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor inhibitor gefitinib in completely resected Stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. Proc ASCO 2010;Abstract LBA7005.

Go to previous Journal Club